Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Risk-adapted modulation through de-intensification of cancer treatments

Dario Trapani and Maria Alice Borinelli-Franzoi explain a need of the oncology/cancer research community that led to the ESMO Precision Medicine Working Group driven project on developing a classification to categorise biomarkers to inform risk-guided intensity modulation of cancer treatments. They describe a methodology applied, how this will help shape better patient information, and explain prospect/utility of this new classification. Recommendations are published in the Annals of Oncology.

Original article: https://www.annalsofoncology.org/article/S0923-7534(22)00669-X/fulltext

Produced by the European Society for Medical Oncology

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.